August 2017 CÚRAM Continues To Strengthen MedTech Ecosystem with New US Industry Partnership

Pioneering project to determine the potential of a synthetic product to advance the study and treatment of respiratory disease

CÚRAM, the Science Foundation Ireland Centre for Research in Medical Devices, based at NUI Galway, has recently signed a collaborative research agreement with Factor Bioscience, a US based biotechnology SME that is pioneering nucleic-acid and cell-based technologies to advance the study and treatment of disease, including respiratory disease. This is the US company’s first collaboration in Ireland.

The project goal is to determine the translational potential of a synthetic product from Factor Bioscience for use in Acute Respiratory Distress Syndrome (ARDS). ARDS often affects the elderly and occurs when fluid builds up in the air sacs in the lungs and prevents them from filling with enough air. This means less oxygen is available to reach the bloodstream which deprives the organs of the oxygen they need to function properly. ARDS typically occurs in people who are already critically ill or who have significant injuries, and many people who develop ARDS don’t survive. Those who do can experience lasting damage to their lungs.

“Factor engages in research collaborations to advance and deploy our technologies as quickly and broadly as possible”, says Matt Angel, Co-founder of Factor Bioscience. “We are an early-stage biotechnology company based in the Boston area with an Irish subsidiary, and we are looking to grow our operations in Ireland. By partnering with CÚRAM on this project we can access leading experts and resources in the medical device field, which will hopefully allow us to progress much faster in finding a better solution for patients suffering from ARDS. Currently we are developing synthetic protein-encoding RNA therapeutics using our patented and patent-pending chemistries and sequences. In the near term, we are interested in expanding our technology in the area of delivering these therapeutics to various tissues and organs in the body.”

Dr Daniel O'Toole, a CÚRAM collaborator in the School of Medicine will coordinate the collaborative laboratory research at NUI Galway, said: “Factor Bioscience has an exciting panel of innovative and highly promising therapeutics that we feel have real potential to address unmet clinical needs. We’re looking forward to developing and testing these for treatment of a range of inflammatory and infectious diseases.”

CÚRAM is working to develop a positive, long lasting impact on the MedTech sector as well as for patients suffering from chronic illness. The global financial cost of managing chronic illnesses are ever increasing and both clinical and economic needs have to be met. CÚRAM’s goal is to come up with affordable solutions to meet these needs.

The project was developed following an introduction to both partners, facilitated by IDA Ireland in Boston. “I am delighted to have been able to make the introduction between CÚRAM and Factor Bioscience and to hear it has resulted in an exciting new research partnership”, said Ivan Houlihan, Vice President of IDA Ireland, Boston. “Making connections and facilitating introductions between companies and third-level institutions and research centres is a key function of IDA Ireland, we try to ensure the necessary skills, experience and research capabilities exist to drive their business forward.”

Professor Abhay Pandit, Scientific Director of CÚRAM, said: “Key to our success is our collaboration with industry partners to continue to enhance medical device technologies and their clinical application. Through collaborations such as these we can strengthen the R&D capability in Ireland to support the growth of a vibrant start up community within the MedTech ecosystem.”

-Ends-